SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 160 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $355 | -26.2% | 24,410 | +6.4% | 0.00% | – |
| Q2 2023 | $481 | +99.6% | 22,939 | +101.9% | 0.00% | – |
| Q1 2023 | $241 | +1.3% | 11,364 | +21.4% | 0.00% | – |
| Q4 2022 | $238 | -99.9% | 9,364 | +11.1% | 0.00% | – |
| Q3 2022 | $203,000 | -97.9% | 8,429 | -98.4% | 0.00% | -100.0% |
| Q3 2021 | $9,863,000 | +36.6% | 516,098 | +22.8% | 0.00% | 0.0% |
| Q2 2021 | $7,219,000 | -26.5% | 420,420 | -4.2% | 0.00% | 0.0% |
| Q1 2021 | $9,816,000 | +157.4% | 439,017 | +156.1% | 0.00% | – |
| Q4 2020 | $3,813,000 | – | 171,439 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |